We repeatedly assessed metabolic and neuropathy parameters longitudinally (e.g. body weight, insulin sensitivity, motor and sensory NCVs, and withdrawal latency to heat) and IENFDs at two terminal time points (20 weeks and 36 weeks); however, we only performed one terminal time point for fat depot mass (36 weeks) and circulating lipid and adipokine levels (20 weeks). Here, INS is linked to neuropathy.